FibroGen, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thane Wettig
- Full Time Employees
- 225
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 409 Illinois Street San Francisco CA United States of America 94158
- IPO Date
- Nov 14, 2014
- CIK
- 0000921299
- Website
- fibrogen.com
- Similar Companies
- Business
- FibroGen, Inc. is a biopharmaceutical company engaged in the development and commercialization of innovative therapies targeting serious unmet medical needs in the areas of oncology, anemia, and fibrotic disease. The company’s core products and pipeline include roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in chronic kidney disease (CKD) and lower-risk myelodysplastic syndromes (LR-MDS) with high red blood cell transfusion burden; pamrevlumab, a monoclonal antibody targeting connective tissue growth factor (CTGF), which is being investigated for idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy; and FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46 for metastatic castration-resistant prostate cancer (mCRPC), alongside its companion PET imaging agent FG-3180. FibroGen offers these therapeutics primarily through clinical development programs and direct marketing where approved, focusing on patient populations with serious chronic or life-threatening conditions across the United States and globally. Founded in 1993 and headquartered in San Francisco, California, FibroGen operates with a strategic focus on cancer biology, fibrosis, and anemia treatment modalities. In the most recent strategic developments, the company completed the sale of its FibroGen China subsidiary to AstraZeneca for approximately $220 million, simplifying its capital structure and extending its cash runway into 2028. This transaction transferred full commercialization rights for roxadustat in China to AstraZeneca, strengthening FibroGen’s financial position and enabling greater operational focus on advancing its pipeline assets. Additionally, FibroGen initiated a Phase 2 monotherapy dose optimization trial of FG-3246 in mCRPC with interim results expected in the second half of 2026, and reached an agreement with the U.S. Food and Drug Administration (FDA) on critical design elements for the pivotal Phase 3 trial of roxadustat in LR-MDS, with the final protocol submission expected by the fourth quarter of 2025. These moves underscore FibroGen’s commitment to advancing late-stage clinical development while optimizing its resource deployment. FibroGen’s product and development platform leverage novel molecular biology insights, including hypoxia-inducible factor (HIF) biology and connective tissue growth factor (CTGF) targeting, to create differentiated therapeutic agents. The company’s commercial and clinical operations extend beyond the United States, with partnerships and collaborations in Asia and other regions that facilitate product development and market access, though its recent divestiture in China marks a re-concentration of efforts in its core markets. FibroGen continues to assess internal development and external partnership opportunities to maximize the commercial potential of its product candidates. The company remains a publicly traded entity under the ticker symbol FGEN, with a focus on delivering innovative treatment options in oncology, anemia, and fibrotic diseases through a robust pipeline and strategic collaborations.
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
FibroGen to Report Third Quarter 2025 Financial Results
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
FibroGen to Report Second Quarter 2025 Financial Results
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session
FibroGen Announces 1-for-25 Reverse Stock Split
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update